[Nonspecific immunotherapy using 2,4,6-trimethylhydroxypyrimidine (OPM-111) in Mycoplasma arthritidis infection in mice].
Intraperitoneal infection of mice with M. anthritidis resulted in development of necrotic lesions in the omentum, mesentery and perirenal fatty tissue. The effect of 2,4,6-trimethyloxypyrimidine on such affections was studied. It was shown that the drug had immunomodulating properties and prevented development of lesions caused by Mycoplasma.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D000942:Antigens, Bacterial / Q000032:analysis; D000975:Antioxidants / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D007167:Immunotherapy / Q000379:methods*; D051379:Mice; D008815:Mice, Inbred Strains; D009174:Mycoplasma / Q000276:immunology; D009175:Mycoplasma Infections / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D009336:Necrosis; D011743:Pyrimidines / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D000942:Antigens, Bacterial; D000975:Antioxidants; D011743:Pyrimidines; C020811:2,4,6-trimethyl-5-hydroxypyrimidine
Nespetsificheskaia immunoterapiia 2,4,6-trimetiloksipirimidinom (OPM-111) pri infektsii mysheĭ Mycoplasma arthritidis.